Healthcare-associated infections (HAIs) are a major cause of morbidity and mortality around the world. An estimated 6 million healthcare-associated infections occur each year across the United States, Europe and Japan alone.* The Centers for Disease Control and Prevention estimates there are 1.7 million infections resulting in approximately 99,000 deaths annually in the United States, making healthcare-associated infections the fourth leading cause of death.* Beyond the human toll, there is an enormous financial burden to healthcare systems worldwide. BD is committed to applying its expertise, resources and technologies toward the prevention of healthcare-associated infections worldwide.

News & Events

[bullet] BD Diagnostics and Biodiversity Collaborate to Develop Portfolio of Assays on the BD MAX™ System »

[bullet] BD and Lab21 Collaborate to Develop Aspergillus Assay for New BD MAX™ Molecular Testing System  »

[bullet] BD Diagnostics Hires Leading Infectious Disease Diagnostics Expert to Strengthen New Product Pipeline »

[bullet] BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases »

[bullet] BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System  »

[bullet] Bruker Announces Integrated Microbiology Workflow For MALDI Biotyper Microbial Identification and BD Phoenix™ Antibiotic Susceptibility Testing »

[bullet] BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians »

[bullet] "VBP (Value-based purchasing) will reward HAI reduction," written by Kathy Warye, VP, Infection Prevention, appears in Medical Laboratory Observer's Washington Report April 2011 issue »

[bullet] BD Receives CE Mark Approval for Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures »

[bullet] World Health Day Emphasis on Antimicrobial Resistance Brings Much-Needed Awareness to Alarming Issue  »

[bullet] New CDC Guidelines Recognize Value of Split Septum IV Access Technology to Reduce Intravascular Catheter-Related Bloodstream Infections  »

[bullet] BD Taps Leading Voice in Infection Prevention Community to Advance Efforts to Reduce Healthcare-Associated Infections »

[bullet] BD Diagnostics and Lonza Collaborate to Commercialize the Lonza microCompass™ Molecular Assays on the BD MAX™ System »

[bullet] BD Diagnostics and Bruker Collaborate to Improve Microbial Identification and Antimicrobial Susceptibility Testing »

[bullet] BD Receives CLIA "Moderate Complexity" Status for the BD MAX™ GBS Assay »

[bullet] BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus  »

[bullet] BD Diagnostics Launches the BD Protect™ Infection Surveillance and Prevention Software Portfolio »

*Data on file at BD.